

Form PTO-1449 (modified)

Atty. Docket No.

UTSC:652US

Serial No.

09/998,009

Office of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

November 28, 2001

Group:

1614

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>n</i>	C1	Agarwal and Mehta, "Possible involvement of Bcl-2 pathway in retinoid X receptor alpha-induced apoptosis of HL-60 cells," <i>Biochem Biophys Res Commun</i> , 230(2):251-253, 1997.
<i>n</i>	C2	Andreeff <i>et al.</i> , "Expression of bcl-2-related genes in normal and AML progenitors: Changes induced by chemotherapy and cationic acid," <i>Leukemia</i> , 13:1881-1892, 1999.
<i>n</i>	C3	Andreeff, "Acute myeloid leukemia," <i>In: Cancer Treatment</i> , Haskell (Ed.), W. B. Saunders, 911-922, 1995.
<i>n</i>	C4	Beran <i>et al.</i> , "Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia," <i>J. Clinical Oncology</i> , 17(9):2819-2830, 1999.
<i>n</i>	C5	Carter <i>et al.</i> , "Expression of survivin, a member of the inhibitor of apoptosis (IAP) family of caspase inhibitors is expressed in AML and regulated by cytokines and ATRA," <i>Blood</i> , 94(Suppl 1):479a, Abstract # 2142, 1999.
<i>n</i>	C6	Castaigne <i>et al.</i> , "All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia," <i>Blood</i> , 76(9):1704-1709, 1990.
<i>n</i>	C7	Drach <i>et al.</i> , "Induction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all-trans-retinoic acid," <i>Cancer Research</i> , 53:2100-2104, 1993.

25117808.1

EXAMINER:

Neale

DATE CONSIDERED:

10/14/04

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSC:652US

09/998,009

Office of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Marina Konopleva *et al.*

Filing Date:

November 28, 2001

Group:

1614

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
h	C8	Engel <i>et al.</i> , "Quantitation of minimal residual disease in acute myelogenous leukemia and myelodysplastic syndromes in complete remission by molecular cytogenetics of progenitor cells," <i>Leukemia</i> , 13:568-577, 1999.
h	C9	Estey <i>et al.</i> , "Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia," <i>Blood</i> , 94:2230-2235, 1999.
h	C10	Estey <i>et al.</i> , "Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin + all-trans retinoic acid + granulocyte-colony stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrom," <i>Blood</i> , 93(8):2478-2484, 1998.
h	C11	Kim <i>et al.</i> , "Capasase-3 activation is involved in apoptosis induced by a synthetic triterpenoid in Non-small cell lung cancer (NSCLC) cells," <i>Proc. Amer. Assoc. Cancer Res.</i> , 41:770, Abstract #4894, 2000.
h	C12	Konopleva and Andreeff, "Regulatory pathways in programmed cell death," <i>Cancer Mol Biol.</i> , 6:1229-1260, 1999.
h	C13	Konopleva <i>et al.</i> , "Apoptosis: molecules and mechanisms," <i>Adv Exp Med Biol</i> , 457:217-236, 1998.
h	C14	Konopleva <i>et al.</i> , "Engraftment potential of AML progenitors into NOD/scid mice is dependent on baseline CXCR4 expression," <i>Blood</i> , 94(Suppl 1):166b, Abstract #3916, 1999.
h	C15	Konopleva <i>et al.</i> , "Novel synthetic triterpenoid, CDDO, and its methyl ester: Potent antiproliferative, proapoptotic and differentiating agents in AML," <i>Blood</i> , 94(Suppl 1):479a, Abstract #2140, 1999.
h	C16	Konopleva <i>et al.</i> , "Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia," <i>Blood</i> , 99(1):326-335, 2002.
h	C17	Konopleva <i>et al.</i> , "PPAR γ nuclear receptor as a novel therapeutic target in AML," <i>Blood</i> , 96(11):460a, Abstract #1982, 2000.
h	C18	Kornblau <i>et al.</i> , "Apoptosis regulating proteins as targets of therapy for hematological malignancies," <i>Exp. Opin. Inv. Drugs</i> , 8:2027-2057, 1999.
h	C19	Kornblau <i>et al.</i> , "Phase I study of mitoxantrone plus etoposide with multidrug blockage by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia," <i>J. Clin. Oncol.</i> , 15(5):1796-1802, 1997.

25117808.1

EXAMINER:

N. Cook

DATE CONSIDERED:

10/14/04

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

RECEIVED

MAY 30 2002

TECH CENTER 1600/2900



Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSC:652US

09/998,009

List of Patents and Publications for Applicant's

Applicant

Marina Konopleva *et al.*

INFORMATION DISCLOSURE STATEMENT

Filing Date:

Group:

November 28, 2001

1614

(Use several sheets if necessary)

U.S. Patent Documents

Foreign Patent Documents

Other Art

See Page 1

See Page 1

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
n	C20	Mehta <i>et al.</i> , "Activation of retinoid receptors RAR alpha and RXR alpha induces differentiation and apoptosis, respectively, in HL-60 cells," <i>Cell, Growth Differ.</i> 7(2): 179-186, 1996.
n	C21	Sporn <i>et al.</i> , "Prospects for prevention and treatment of cancer with selective PPAR γ modulators (SPARMs)," <i>Trends in Molecular Medicine</i> , 7(9):395-400, 2001.
b	C22	Suh <i>et al.</i> , "A novel synthetic oleanane triterpenoid, 2-cyano-3, 12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity," <i>Cancer Res.</i> , 59(2):336-341, 1999.
n	C23	Tamm <i>et al.</i> , "Expression and prognostic significance of IAP-family genes in human cancers and leukemias," <i>Blood</i> , 94(Suppl. 1):69a, Abstract # 298, 1999.
n	C24	Walczak <i>et al.</i> , "Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand <i>in vivo</i> ," <i>Nature Medicine</i> , 5(2):157-163, 1999.
n	C25	Wang <i>et al.</i> , "A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma," <i>Mol.Endocrinol.</i> , 14(10): 1550-1556, 2000.
a	C26	Warrell <i>et al.</i> , "Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid)," <i>N. Engl. J. Med.</i> , 324(20):1385-1393, 1991.
n	C27	Xie <i>et al.</i> , "Differential expression patterns in human myeloblastic leukemia HL-60 and multidrug resistant HL-60/Dox cells analyzed by human cDNA expression array," <i>Blood</i> , 92 (Suppl 1):387a, Abstract #1600. 1998.

25117808.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

UTSC:652US

09/998,009

List of Patents and Publications for Applicant's

Applicant

Marina Konopleva *et al.*

INFORMATION DISCLOSURE STATEMENT

Filing Date:

Group:

November 28, 2001

1635

(Use several sheets if necessary)

U.S. Patent Documents

Foreign Patent Documents

Other Art

See Page 1

See Page 1

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
W	B1	WO 99/65478	12/23/99	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
W	C28	Ito <i>et al.</i> , "The novel triterpenoid 2-cyano-3, 12-dioxoolean-1,9-dien-28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism," <i>Cell Growth & Differentiation</i> , 11(5):261-267, 2000.
W	C29	Konopleva <i>et al.</i> , "Novel synthetic triterpenoid CDDO-Me: potent antiproliferative, proapoptotic and differentiating agent in AML," <i>Blood</i> , 96(11), Part 1: 121A, abstract # 522, 2000.
W	C30	Ruvolo <i>et al.</i> , "The novel triterpenoid methyl-CDDO inhibits Bc12 phosphorylation and potentially kills U937 cells," <i>Blood</i> , 94(10), Suppl. 1, Part 1: 280A, abstract #1251, 1999.
W	C31	Suh <i>et al.</i> , "A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO), induces cell differentiation in human myeloid leukemias," <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> , 40:300, abstract # 1988, 1999.
W	C32	Wang <i>et al.</i> , "A novel synthetic triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO) induces adipocyte differentiation in 3T3-L1 cells," <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> , 40:300, abstract # 1989, 1999.

25280096.1

EXAMINER:

Nlooh

DATE CONSIDERED:

10/14/04

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



RECEIVED
APR 30 2003
TECH CENTER 1600/2900